“The field force expansion done in FY21 has met with good success and considering the current market conditions, we will be undertaking a further expansion of about 10 per cent for our field force in FY23, driven by the twin objectives of brand focus and geographical expansion,” Sun Pharmaceutical Industries CEO (India Business) Kirti Ganorkar said in an analyst call.
